<table border="0" cellpadding="0" cellspacing="0" width="599" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<tbody>
<tr stylecode="Botrule">
<td align="center" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Concomitant Drug</content>
<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="bold">Effect on</content>
<br/>
<content stylecode="bold">Concentration of</content>
<br/>
<content stylecode="bold">Lamotrigine or</content>
<br/>
<content stylecode="bold">Concomitant Drug</content>
<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="bold">Clinical Comment</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Estrogen-containing oral contraceptive preparations containing 30 mcg ethinylestradiol and 150 mcg levonorgestrel<br/>
</td>
<td stylecode="Rrule" valign="top">↓ lamotrigine<br/> <br/> <br/>↓ levonorgestrel<br/>
</td>
<td stylecode="Rrule" valign="top">Decreased lamotrigine concentrations approximately 50%.<br/>Decrease in levonorgestrel component by 19%.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Carbamazepine <br/>and carbamazepine epoxide<br/>
</td>
<td stylecode="Rrule" valign="top">↓ lamotrigine<br/> <br/> <br/> <br/>? carbamazepine epoxide<br/>
</td>
<td stylecode="Rrule" valign="top">Addition of carbamazepine decreases lamotrigine concentration approximately 40%.<br/> <br/>May increase carbamazepine epoxide levels.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Lopinavir/ritonavir <br/>
</td>
<td stylecode="Rrule" valign="top">↓ lamotrigine <br/>
</td>
<td stylecode="Rrule" valign="top">Decreased lamotrigine concentration approximately 50%. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Atazanavir/ritonavir <br/>
</td>
<td stylecode="Rrule" valign="top">↓ lamotrigine <br/>
</td>
<td stylecode="Rrule" valign="top">Decreased lamotrigine AUC approximately 32%. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Phenobarbital/primidone<br/>
</td>
<td stylecode="Rrule" valign="top">↓ lamotrigine<br/>
</td>
<td stylecode="Rrule" valign="top">Decreased lamotrigine concentration approximately 40%.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Phenytoin <br/>
</td>
<td stylecode="Rrule" valign="top">↓ lamotrigine<br/>
</td>
<td stylecode="Rrule" valign="top">Decreased lamotrigine concentration approximately 40%.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Rifampin<br/>
</td>
<td stylecode="Rrule" valign="top">↓ lamotrigine<br/>
</td>
<td stylecode="Rrule" valign="top">Decreased lamotrigine AUC approximately 40%.<br/>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule" valign="top">Valproate<br/>
</td>
<td stylecode="Rrule" valign="top">↑ lamotrigine<br/> <br/> <br/> <br/>? valproate<br/>
</td>
<td stylecode="Rrule" valign="top">Increased lamotrigine concentrations slightly more than 2-fold. <br/> <br/>There are conflicting study results regarding effect of lamotrigine on valproate concentrations: 1) a mean 25% decrease in valproate concentrations in healthy volunteers, 2) no change in valproate concentrations in controlled clinical trials in patients with epilepsy. <br/>
</td>
</tr>
</tbody>
</table>